Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalized with COVID-19: A protocol for a pragmatic clinical trial

Justin Z Chen, Holly L Hoang, Maryna Yaskina, Dima Kabbani, Karen E Doucette, Stephanie W Smith, Cecilia Lau, Jackson Stewart, Karen Zurek, Morgan Schultz, Carlos Cervera, Justin Z Chen, Holly L Hoang, Maryna Yaskina, Dima Kabbani, Karen E Doucette, Stephanie W Smith, Cecilia Lau, Jackson Stewart, Karen Zurek, Morgan Schultz, Carlos Cervera

Abstract

Background: The use of broad-spectrum antibiotics is widespread in patients with COVID-19 despite a low prevalence of bacterial co-infection, raising concerns for the accelerated development of antimicrobial resistance. Antimicrobial stewardship (AMS) is vital but there are limited randomized clinical trial data supporting AMS interventions such as prospective audit and feedback (PAF). High quality data to demonstrate safety and efficacy of AMS PAF in hospitalized COVID-19 patients are needed.

Methods and design: This is a prospective, multi-center, non-inferiority, pragmatic randomized clinical trial evaluating AMS PAF intervention plus standard of care (SOC) versus SOC alone. We include patients with microbiologically confirmed SARS-CoV-2 infection requiring hospital admission for severe COVID-19 pneumonia. Eligible ward beds and critical care unit beds will be randomized prior to study commencement at each participating site by computer-generated allocation sequence stratified by intensive care unit versus conventional ward in a 1:1 fashion. PAF intervention consists of real time review of antibacterial prescriptions and immediate written and verbal feedback to attending teams, performed by site-based AMS teams comprised of an AMS pharmacist and physician. The primary outcome is clinical status at post-admission day 15 measured using a 7-point ordinal scale. Patients will be followed for secondary outcomes out to 30 days. A total of 530 patients are needed to show a statistically significant non-inferiority, with 80% power and 2.5% one-sided alpha assuming standard deviation of 2 and the non-inferiority margin of 0.5.

Discussion: This study protocol presents a pragmatic clinical trial design with small unit cluster randomization for AMS intervention in hospitalized COVID-19 that will provide high-level evidence and may be adopted in other clinical situations.

Trial registration: This study is being performed at the University of Alberta and is registered at ClinicalTrials.gov (NCT04896866) on May 17, 2021.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. SPIRIT schedule of enrollment, interventions,…
Fig 1. SPIRIT schedule of enrollment, interventions, and assessments.

References

    1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–4. doi: 10.1016/S1473-3099(20)30120-1
    1. MacIntyre CR, Chughtai AA, Barnes M, Ridda I, Seale H, Toms R, et al.. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09. BMC Infect Dis. 2018;18(1):637. doi: 10.1186/s12879-018-3548-0
    1. Shah NS, Greenberg JA, McNulty MC, Gregg KS, Riddell Jt, Mangino JE, et al.. Bacterial and viral co-infections complicating severe influenza: Incidence and impact among 507 U.S. patients, 2013–14. J Clin Virol. 2016;80:12–9. doi: 10.1016/j.jcv.2016.04.008
    1. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al.. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622–9. doi: 10.1016/j.cmi.2020.07.016
    1. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al.. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa530
    1. Popp M, Stegemann M, Riemer M, Metzendorf MI, Romero CS, Mikolajewska A, et al.. Antibiotics for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;10:CD015025. doi: 10.1002/14651858.CD015025
    1. Polgreen PM, Chen YY, Cavanaugh JE, Ward M, Coffman S, Hornick DB, et al.. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol. 2007;28(2):212–4. doi: 10.1086/512174
    1. Sapp JL, Alqarawi W, MacIntyre CJ, Tadros R, Steinberg C, Roberts JD, et al.. Guidance On Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. The Canadian journal of cardiology. 2020. doi: 10.1016/j.cjca.2020.04.003
    1. Langford BJ, So M, Raybardhan S, Leung V, Soucy JR, Westwood D, et al.. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27(4):520–31. doi: 10.1016/j.cmi.2020.12.018
    1. Manesh A, Varghese GM, Investigators C, Collaborators. Rising antimicrobial resistance: an evolving epidemic in a pandemic. Lancet Microbe. 2021;2(9):e419–e20. doi: 10.1016/S2666-5247(21)00173-7
    1. Mazdeyasna H, Nori P, Patel P, Doll M, Godbout E, Lee K, et al.. Antimicrobial Stewardship at the Core of COVID-19 Response Efforts: Implications for Sustaining and Building Programs. Curr Infect Dis Rep. 2020;22(9):23. doi: 10.1007/s11908-020-00734-x
    1. Clancy CJ, Nguyen MH. COVID-19, superinfections and antimicrobial development: What can we expect? Clin Infect Dis. 2020.
    1. Stevens MP, Patel PK, Nori P. Involving antimicrobial stewardship programs in COVID-19 response efforts: all hands on deck. Infection Control & Hospital Epidemiology. 2020:1–6.
    1. Le Saux NMA, Bowes J, Viel-Theriault I, Thampi N, Blackburn J, Buba M, et al.. Combined influence of practice guidelines and prospective audit and feedback stewardship on antimicrobial treatment of community-acquired pneumonia and empyema in children: 2012 to 2016. Paediatr Child Health. 2021;26(4):234–41. doi: 10.1093/pch/pxaa066
    1. Livorsi DJ, Nair R, Dysangco A, Aylward A, Alexander B, Smith MW, et al.. Using Audit and Feedback to Improve Antimicrobial Prescribing in Emergency Departments: A Multicenter Quasi-Experimental Study in the Veterans Health Administration. Open Forum Infect Dis. 2021;8(6):ofab186. doi: 10.1093/ofid/ofab186
    1. Alsaggaf R, O’Hara LM, Stafford KA, Leekha S, Harris AD, Program CDCPE. Quasi-experimental Studies in the Fields of Infection Control and Antibiotic Resistance, Ten Years Later: A Systematic Review. Infect Control Hosp Epidemiol. 2018;39(2):170–6. doi: 10.1017/ice.2017.296
    1. Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, Perencevich EN. The use and interpretation of quasi-experimental studies in infectious diseases. Clin Infect Dis. 2004;38(11):1586–91. doi: 10.1086/420936
    1. Nathwani D, Varghese D, Stephens J, Ansari W, Martin S, Charbonneau C. Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review. Antimicrob Resist Infect Control. 2019;8:35. doi: 10.1186/s13756-019-0471-0
    1. The COVID-19 Antimicrobial Management Working Group AHS. Current Guidance for the Management of Adult Hospitalized Patients with COVID-19: Alberta Health Services; 2020 [Available from: ].
    1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al.. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81. doi: 10.1111/j.1469-0691.2011.03570.x
    1. Veiga VC, Prats J, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, et al.. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:n84. doi: 10.1136/bmj.n84
    1. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, et al.. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62(10):e51–77. doi: 10.1093/cid/ciw118
    1. Schweizer ML, Braun BI, Milstone AM. Research Methods in Healthcare Epidemiology and Antimicrobial Stewardship-Quasi-Experimental Designs. Infect Control Hosp Epidemiol. 2016;37(10):1135–40. doi: 10.1017/ice.2016.117
    1. Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, et al.. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017;2:CD003543. doi: 10.1002/14651858.CD003543.pub4
    1. Schuts EC, Hulscher M, Mouton JW, Verduin CM, Stuart J, Overdiek H, et al.. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):847–56. doi: 10.1016/S1473-3099(16)00065-7
    1. Schweitzer VA, van Heijl I, van Werkhoven CH, Islam J, Hendriks-Spoor KD, Bielicki J, et al.. The quality of studies evaluating antimicrobial stewardship interventions: a systematic review. Clin Microbiol Infect. 2019;25(5):555–61. doi: 10.1016/j.cmi.2018.11.002
    1. McGowan JE. Antimicrobial stewardship—the state of the art in 2011: focus on outcome and methods. Infect Control Hosp Epidemiol. 2012;33(4):331–7. doi: 10.1086/664755
    1. Morris AM. Antimicrobial Stewardship Programs: Appropriate Measures and Metrics to Study their Impact. Curr Treat Options Infect Dis. 2014;6(2):101–12. doi: 10.1007/s40506-014-0015-3
    1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al.. Remdesivir for the Treatment of Covid-19—Final Report. N Engl J Med. 2020;383(19):1813–26. doi: 10.1056/NEJMoa2007764
    1. Wagner B, Filice GA, Drekonja D, Greer N, MacDonald R, Rutks I, et al.. Antimicrobial stewardship programs in inpatient hospital settings: a systematic review. Infect Control Hosp Epidemiol. 2014;35(10):1209–28. doi: 10.1086/678057
    1. Dhamanaskar R, Merz JF. High-impact RCTs without prospective informed consent: a systematic review. J Investig Med. 2020;68(8):1341–8. doi: 10.1136/jim-2020-001481
    1. Flory JH, Mushlin AI, Goodman ZI. Proposals to Conduct Randomized Controlled Trials Without Informed Consent: a Narrative Review. J Gen Intern Med. 2016;31(12):1511–8. doi: 10.1007/s11606-016-3780-5
    1. Giraudeau B, Caille A, Le Gouge A, Ravaud P. Participant informed consent in cluster randomized trials: review. PLoS One. 2012;7(7):e40436. doi: 10.1371/journal.pone.0040436
    1. London AJ, Taljaard M, Weijer C. Loopholes in the Research Ethics System? Informed Consent Waivers in Cluster Randomized Trials with Individual-Level Intervention. Ethics Hum Res. 2020;42(6):21–8. doi: 10.1002/eahr.500071
    1. McRae AD, Weijer C, Binik A, Grimshaw JM, Boruch R, Brehaut JC, et al.. When is informed consent required in cluster randomized trials in health research? Trials. 2011;12:202. doi: 10.1186/1745-6215-12-202
    1. Sim J, Dawson A. Informed consent and cluster-randomized trials. Am J Public Health. 2012;102(3):480–5. doi: 10.2105/AJPH.2011.300389
    1. Getahun H, Smith I, Trivedi K, Paulin S, Balkhy HH. Tackling antimicrobial resistance in the COVID-19 pandemic. Bull World Health Organ. 2020;98(7):442–A. doi: 10.2471/BLT.20.268573
    1. Ashiru-Oredope D, Kerr F, Hughes S, Urch J, Lanzman M, Yau T, et al.. Assessing the Impact of COVID-19 on Antimicrobial Stewardship Activities/Programs in the United Kingdom. Antibiotics (Basel). 2021;10(2). doi: 10.3390/antibiotics10020110

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅